About
Science Corporation is a clinical-stage medical technology company building full-stack neural engineering platforms to address some of medicine's most challenging unmet needs. Their flagship product, PRIMA, is a BCI-based retinal implant designed to restore vision for patients suffering from macular degeneration, retinitis pigmentosa, and Stargardt disease — conditions with no existing treatment options. The PRIMA system leverages photovoltaic subretinal implants combined with laser projection optics to stimulate surviving retinal neurons, effectively bypassing damaged photoreceptors. Beyond vision restoration, Science is developing Biohybrid neural interfaces that connect to the brain using living neurons, and Vessel, a perfusion technology aimed at supporting and extending life. Their integrated ecosystem includes proprietary tools such as the SciFi Headstage, Synapse Protocol, Axon Probes, and Nexus platform — enabling cutting-edge neural recording and stimulation. Through their Foundry division, Science offers external researchers and companies access to their advanced microfabrication capabilities and neural engineering expertise, supporting collaborations from research-stage to commercial production. With $230 million in Series C funding closed in 2026 and breakthrough results published in the New England Journal of Medicine, Science Corporation is at the forefront of clinical BCI innovation, aiming to transcend the biological limits that cause debilitating neurological and sensory conditions.
Key Features
- PRIMA BCI Retinal Implant: A photovoltaic subretinal implant that restores vision for patients with macular degeneration, retinitis pigmentosa, and Stargardt disease by bypassing damaged photoreceptors.
- Biohybrid Neural Interfaces: Next-generation neural interfaces that connect to the brain using living neurons, opening entirely new possibilities in neural engineering.
- Vessel Perfusion Technology: Advanced organ perfusion technology designed to support and extend life, positioning perfusion as a long-term solution rather than a temporary bridge.
- Full-Stack Neural Engineering Ecosystem: A proprietary suite of tools — including SciFi Headstage, Synapse Protocol, Axon Probes, and Nexus — enabling comprehensive neural recording and stimulation.
- Foundry Services: Commercial microfabrication and neural engineering capabilities available to external researchers and companies, accelerating projects from research to production.
Use Cases
- Restoring functional vision to patients with advanced macular degeneration or retinitis pigmentosa through the PRIMA retinal implant in clinical trials.
- Enabling academic and commercial research teams to access cutting-edge neural microfabrication through the Science Foundry.
- Supporting organ preservation and perfusion research via Science's Vessel technology platform.
- Advancing brain-computer interface ecosystems through commercial BCI partnerships and the company's proprietary neural engineering toolkit.
- Exploring biohybrid neural interfaces for next-generation neuroprosthetics and long-term brain-machine integration research.
Pros
- Pioneering Clinical BCI Research: Science has published breakthrough results in the New England Journal of Medicine and raised $230M in Series C funding, demonstrating strong clinical and commercial momentum.
- Vertically Integrated Platform: By controlling the full stack — from neural recording electronics to laser projection optics — Science can iterate faster and maintain tighter quality control than competitors.
- Open Foundry Collaboration: External researchers and companies can leverage Science's advanced microfabrication capabilities, lowering the barrier for neural engineering innovation.
Cons
- Clinical-Stage Only: Products are not yet commercially available to the general public; access is limited to clinical trial participants and select research partners.
- Narrow Patient Indication (Current): The current PRIMA implant targets specific degenerative retinal diseases, limiting the addressable patient population in the near term.
Frequently Asked Questions
What is the PRIMA implant and who is it for?
PRIMA is a BCI-based subretinal implant designed to restore vision in patients with degenerative retinal diseases such as macular degeneration, retinitis pigmentosa, and Stargardt disease, for whom no other treatment options exist.
Is Science Corporation's technology available to the public?
Science Corporation is currently in clinical trials. Interested patients can join the patient registry on their website to learn about eligibility for ongoing trials.
What is Science Corporation's Foundry?
The Foundry is Science's commercial division that offers access to their advanced microfabrication capabilities and neural engineering tools to external research institutions and companies looking to develop next-generation medical devices.
What is a Biohybrid neural interface?
Biohybrid interfaces are a novel class of neural devices that use living neurons to form connections with the brain, enabling more natural and potentially more stable integration than traditional electrode-based approaches.
How can I collaborate with Science Corporation?
Organizations interested in BCI ecosystem partnerships or Foundry services can reach out through the Science Corporation website. Recent partnerships include collaborations with companies like Neurosoft Bioelectronics.
